About newamsterdam pharma co nv - NAMS
NewAmsterdam Pharma Co. NV is a clinical-stage biopharmaceutical company, which engages in the development of oral, non-statin medicine for patients at high risk of cardiovascular disease with residual elevation of low-density lipoprotein cholesterol. Its lead product candidate, Obicetrapib, is a next-generation, oral, low-dose cholesteryl ester transfer protein inhibitor, which will be used to prevent major adverse cardiovascular events. The company was founded on June 10, 2022 and is headquartered in Naarden, the Netherlands.
NAMS At a Glance
NewAmsterdam Pharma Co. NV
Gooimeer 2-35
Naarden, Noord-Holland 1411 DC
| Phone | 31-35-206-29-71 | Revenue | 22.50M | |
| Industry | Pharmaceuticals: Major | Net Income | -203,819,000.00 | |
| Sector | Health Technology | Employees | 100 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
NAMS Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 184.612 |
| Price to Book Ratio | 5.872 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -15.599 |
| Enterprise Value to Sales | 156.289 |
| Total Debt to Enterprise Value | 0.00 |
NAMS Efficiency
| Revenue/Employee | 225,030.00 |
| Income Per Employee | -2,038,190.00 |
| Receivables Turnover | 0.972 |
| Total Asset Turnover | 0.028 |
NAMS Liquidity
| Current Ratio | 7.876 |
| Quick Ratio | 7.876 |
| Cash Ratio | 7.432 |
NAMS Profitability
| Gross Margin | 99.022 |
| Operating Margin | -1,002.902 |
| Pretax Margin | -905.741 |
| Net Margin | -905.741 |
| Return on Assets | -24.949 |
| Return on Equity | -28.29 |
| Return on Total Capital | -29.814 |
| Return on Invested Capital | -28.285 |
NAMS Capital Structure
| Total Debt to Total Equity | 0.03 |
| Total Debt to Total Capital | 0.03 |
| Total Debt to Total Assets | 0.026 |
| Long-Term Debt to Equity | 0.01 |
| Long-Term Debt to Total Capital | 0.01 |